Provention Bio Inc. (PRVB) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
August 4, 2022 7:00 AM EDT-Teplizumab Biologics License Application (BLA) user fee goal date extended to November 17, 2022-
-Company completes $60.0 million private placement-
RED BANK, N.J., Aug. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the second quarter ended June 30, 2022, and provided a business update.
